Repeated Response and severe Side Effects with Nivolumab and Ipilimumab and Ipilimumab Monotherapy, but not with Pembrolizumab, in a Patient with mucosal Melanoma

被引：0
|
作者：
Lehner, G. M. [1 ]
Moehn, N. [2 ]
Ivanyi, P. [3 ]
Skripuletz, T. [2 ]
Beutel, G. [3 ]
Satzger, I. [1 ]
Gutzmer, R. [1 ]
机构：
[1] Hauttumorzentrum Hannover, Dermatol, Hannover, Germany
[2] Hannover Med Sch, Neurol, Hannover, Germany
[3] Hannover Med Sch, Hamatol, Hamostaseol, Hannover, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2020年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P102
引用
收藏
页码：70 / 71
页数：2
相关论文
共 50 条
  • [1] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Dummer, R.
    Smylie, M.
    Rutkowski, P.
    Ferrucci, P. F.
    Hill, A.
    Wagstaff, J.
    Carlino, M. S.
    Haanen, J. B.
    Maio, M.
    Marquez-Rodas, I.
    McArthur, G. A.
    Ascierto, P. A.
    Long, G. V.
    Callahan, M. K.
    Postow, M. A.
    Grossmann, K.
    Sznol, M.
    Dreno, B.
    Bastholt, L.
    Yang, A.
    Rollin, L. M.
    Horak, C.
    Hodi, F. S.
    Wolchok, J. D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (01): : 23 - 34
  • [2] HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    Moshyk, A.
    Kotapati, S.
    VALUE IN HEALTH, 2019, 22 : S72 - S73
  • [3] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Ravi Potluri
    Sandip Ranjan
    Hitesh Bhandari
    Helen Johnson
    Andriy Moshyk
    Srividya Kotapati
    Experimental Hematology & Oncology, 8
  • [4] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Potluri, Ravi
    Ranjan, Sandip
    Bhandari, Hitesh
    Johnson, Helen
    Moshyk, Andriy
    Kotapati, Srividya
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (1)
  • [5] COMPARISON OF HEALTHCARE COSTS IN FRANCE OF COMBINATION NIVOLUMAB AND IPILIMUMAB TREATMENT VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Bregman, B.
    Moshyk, A.
    Johnson, H. M.
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    VALUE IN HEALTH, 2020, 23 : S441 - S441
  • [6] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma REPLY
    Larkin, James
    Hodi, F. Stephen
    Wolchok, Jedd D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (13): : 1270 - 1271
  • [7] Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab plus nivolumab
    Hantel, Andrew
    Gabster, Brooke
    Cheng, Jason X.
    Golomb, Harvey
    Gajewski, Thomas F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [8] Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
    Ribas, Antoni
    Martin-Algarra, Salvador
    Bhatia, Shailender
    Hwu, Wen-Jen
    Slingluff, Craig L.
    Sharfman, William H.
    Hodi, F. Stephen
    Urba, Walter J.
    Luke, Jason J.
    Haanen, John B.
    Callahan, Margaret K.
    Wolchok, Jedd D.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Young, Tina C.
    Qureshi, Anila
    Horak, Christine E.
    CANCER RESEARCH, 2017, 77
  • [9] Cutaneous manifestations of ipilimumab, nivolumab and pembrolizumab therapy in patients with advanced melanoma
    Kumar, Anagha Bangalore
    Bryce, Alan
    Vishnu, Prakash
    Markovic, Svetomir
    McEvoy, Marian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB188 - AB188
  • [10] WHAT IS THE IMPACT OF THE INTRODUCTION OF IPILIMUMAB, PEMBROLIZUMAB, AND NIVOLUMAB ON MALIGNANT MELANOMA IN NORDICS?
    Mangat, G.
    Sharma, S.
    VALUE IN HEALTH, 2021, 24 : S42 - S42
12345